Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia

NCT04348799 | Completed

• 1 other identifier: Guangdong W C H
• Study Type: observational
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the relationship between bronchopulmonary dysplasia and thrombocytopenia.

Conditions

Bronchopulmonary Dysplasia; Thrombocytopenia; Preterm Infant

Outcome Measures

Primary Outcomes (1)

• Platelet counts and Circulating MK counts

  Platelet counts and Circulating MK counts

  up to 4 weeks

Secondary Outcomes (3)

• CD62P and CD63 expression

  up to 4 weeks

• TPO

  up to 4 weeks

• TPO and platelet

  up to 6 weeks

Study Arms (2)

BPD group

premature infants diagnosed with BPD after postnatal day 28

Other: BPD

control group

premature infants without BPD after postnatal day 28

Interventions

BPD OTHER

It is a observation research.we didn't intervene anything.

BPD group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Bronchopulmonary dysplasia (BPD) is one of the common complications in neonatal intensive care units (NICU), mainly occurs in premature infants and is considered to be the main cause of premature death

You may qualify if:

• presence of clinical and radiologic signs of BPD, according to conventional criteria (Greenough, 1992);
• presence of peripheral arterial catheter;
• gestation \<32 weeks;
• birth weight \<1.5 kg;
• requiring mechanical ventilation for the treatment of respiratory distress syndrome for at least 3 days during the first weeks of life;
• ventilator and/or oxygen dependent at time of enrolment;

You may not qualify if:

• congenital abnormalities;
• infection (bacteria infection confirmed by positive blood culture or viral infection confirmed by serological test or viral culture)
• evidence of complications of perinatal asphyxia including an apgar score \<3 at one or five minute after birth, evidence of hypoxic-ischemic encephalopathy, acute tubular necrosis, or transient myocardial ischemia;
• identifiable hematologic disease;

Sponsors & Collaborators

• yangjie: lead

Study Sites (1)

Jie Yang

Guangzhou, Guangdong, 511442, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Peripheral arterial blood

MeSH Terms

Conditions

Bronchopulmonary Dysplasia; Thrombocytopenia; Premature Birth

Condition Hierarchy (Ancestors)

Ventilator-Induced Lung Injury; Lung Injury; Lung Diseases; Respiratory Tract Diseases; Infant, Premature, Diseases; Infant, Newborn, Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Blood Platelet Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Cytopenia; Obstetric Labor, Premature; Obstetric Labor Complications; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director of Dept of Neonatology

Study Record Dates

• First Submitted: March 15, 2020
• First Posted: April 16, 2020
• Study Start: January 1, 2019
• Primary Completion: January 1, 2020
• Study Completion: January 1, 2020
• Last Updated: April 16, 2020

Record last verified: 2020-04

Locations

CN (1)